

Supplemental Table 2: Coagulation assay data at admission for patients taking pre-hospital rivaroxaban based on dose and reported time since last dose.

A. Univariate analysis (ANOVA) of effect of time since last reported rivaroxaban dose on coagulation assays

Time since last reported dose	TEG R-time (min); mean (sd)	TEG6S R-time (min); mean (sd)	Rivaroxaban level (ng/mL); mean (sd)	PT Neoplastine (seconds); mean (sd)
10 mg (N=9)				
0-12 hours (n=3)	7.1 (1.98)	6.25 (0.78)	346.8 (409.9)	17.4 (6.5)
12-24 hours (n=2)	4.9 (0.99)	6.3 (1.27)	48.6 (82.9)	11.05 (0.9)
>24 hours (n=4)	5.45 (1.43)	6.09 (1.50)	142.5 (124.0)	13.4 (0.8)
p-value	0.366	0.981	0.425	0.195
15 mg (N=20)				
0-12 hours (n=6)	7.3 (1.47)	7.33 (1.47)	31.2 (36.9)	12.8 (4.4)
12-24 hours (n=9)	5.6 (2.03)	5.6 (2.03)	247.5 (187.3)	16.7 (2.8)
>24 hours (n=5)	4.98 (2.18)	4.98 (2.18)	139.8 (155.7)	12.5 (3.4)
p-value	0.286	0.385	0.150	0.053
20 mg (N=51)				
0-12 hours (n=23)	6.64 (1.41)	6.64 (1.41)	156.0 (171.4)	16.2 (5.4)
12-24 hours (n=17)	5.75 (2.19)	5.75 (2.19)	92.1 (83.2)	13.4 (2.8)
>24 hours (n=11)	4.87 (1.15)	4.87 (1.15)	134.8 (128.8)	13.5 (3.1)
p-value	0.046	0.030	0.465	0.141

B. Multivariable linear regression describing effect of covariates on TEG and TEG6S R-time

Variable	TEG R-time (minutes)			TEG6S R-time (minutes)		
	Coefficient	95% CI	p-value	Coefficient	95% CI	p-value
Last dose (hours)						
0-12*	--	--	--	--	--	--
12-24	-0.99	-2.05, 0.07	0.066	-0.07	-1.31, 1.17	0.913
>24	-1.69	-2.77, 0.61	0.003	-1.72	-3.00, -0.46	0.008
Dose (mg)	0.02	-0.43, 0.47	0.930	0.36	-0.16, 0.88	0.167
Renal function	-0.43	-1.31, 0.46	0.340	-0.81	-1.84, 0.22	0.122
Age	0.05	-0.89, 0.99	0.916	-0.20	-1.34, 0.93	0.721

*Regression coefficients for last dose variable are in reference to baseline 0-12 hours.

ANOVA=Analysis of variance; TEG=Thromboelastography; sd=standard deviation; 95% CI=95% Confidence Interval.